Nuwellis(US:NUWE)2026-03-10 14:00Financial Data and Key Metrics Changes - Full-year revenue for 2025 was $8.3 million, a 5% decrease compared to 2024, primarily due to lower consumables utilization and reduced international contributions [12] - Fourth quarter revenue was $2.4 million, representing a 4% increase year-over-year and a 9% sequential increase, driven by a 208% increase in U.S. console sales [10][11] - Gross margin for the fourth quarter improved to 68.2%, up 9.9 percentage points from the prior year [11] - Full-year operating expenses were $16.2 million, slightly lower than the prior year, reflecting improved expense discipline [12] Business Line Data and Key Metrics Changes - U.S. console sales increased by 208%, with 8 units sold compared to 3 in the prior year [10] - Heart failure and pediatrics segments grew by 8% and 14% year-over-year, respectively, while critical care revenue declined by 19% [12] - International sales increased by 59% year-over-year, largely due to last-time buys from distributors [10] Market Data and Key Metrics Changes - The company reduced exposure in certain international markets, particularly in the European Union, where it had been losing money [18] - The focus has shifted towards geographies with more predictable clinical demand and commercial conversion [5] Company Strategy and Development Direction - The company has clarified its strategic focus around the cardiorenal continuum, emphasizing the interrelation between cardiac and renal conditions [6] - A significant operational change included transitioning manufacturing to KDI Precision Manufacturing to enhance reliability and scalability [5] - The company aims to concentrate resources in areas with strong clinical adoption and economic value, rather than broad-based expansion [9] Management's Comments on Operating Environment and Future Outlook - Management described 2025 as a year of structural change and repositioning, with a focus on operational strengthening and strategic clarity [4][28] - The company plans to maintain financial rigor, strengthen margin consistency, and prioritize capital efficiency as it scales [29] - The integration of the Rendiatech acquisition is expected to enhance utilization within existing accounts, particularly in critical care [25] Other Important Information - The company ended the year with approximately $1.2 million in cash and no outstanding debt, emphasizing liquidity management as a priority [5][12] - The company received a National Institutes of Health grant to support pediatric device development, reinforcing the importance of this area [7][19] Q&A Session Summary Question: Discussion on operational changes and sales focus - Management reinforced the direct sales team and focused on increasing utilization within existing accounts, particularly in critical care [17][24] Question: Inquiry about the Rendiatech acquisition - The acquisition is expected to enhance capabilities in critical care, particularly in measuring renal output and electrolytes at the bedside [20][21]